| Authors: |
Ledermann JA; UCL Cancer Institute, Cancer Research UK & UCL Trials Centre, London, UK. Electronic address: j.ledermann@ucl.ac.uk., Embleton-Thirsk AC; UCL Comprehensive Clinical Trials Unit, London, UK., Perren TJ; Leeds Institute of Medical Research at St James's, Leeds, UK., Jayson GC; Christie Hospital and University of Manchester, Manchester, UK., Rustin GJS; Mount Vernon Cancer Centre, London, UK., Kaye SB; Royal Marsden Hospital, London, UK., Hirte H; Juravinski Cancer Centre, Hamilton, Canada., Oza A; Princess Margaret Cancer Centre, Toronto, Canada., Vaughan M; Christchurch Hospital, Christchurch, New Zealand., Friedlander M; Prince of Wales Clinical School, University of New South Wales, Sydney, Australia., González-Martín A; Clínica Universidad de Navarra, Madrid, Spain., Deane E; UCL Comprehensive Clinical Trials Unit, London, UK., Popoola B; Medical Research Council Clinical Trials Unit at UCL, London, UK., Farrelly L; UCL Cancer Institute, Cancer Research UK & UCL Trials Centre, London, UK., Swart AM; University of East Anglia, Norwich, UK., Kaplan RS; Medical Research Council Clinical Trials Unit at UCL, London, UK., Parmar MKB; Medical Research Council Clinical Trials Unit at UCL, London, UK. |
